Bleeding avoidance strategies in percutaneous coronary intervention
For many years, bleeding has been perceived as an unavoidable consequence of strategies
aimed at reducing thrombotic complications in patients undergoing percutaneous coronary …
aimed at reducing thrombotic complications in patients undergoing percutaneous coronary …
De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an …
DA Gorog, JL Ferreiro, I Ahrens, J Ako… - Nature Reviews …, 2023 - nature.com
Conventional dual antiplatelet therapy (DAPT) for patients with acute coronary syndromes
undergoing percutaneous coronary intervention comprises aspirin with a potent P2Y …
undergoing percutaneous coronary intervention comprises aspirin with a potent P2Y …
P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events
F Gragnano, D Cao, L Pirondini, A Franzone… - Journal of the American …, 2023 - jacc.org
Background Aspirin is the only antiplatelet agent with a Class I recommendation for long-
term prevention of cardiovascular events in patients with coronary artery disease (CAD) …
term prevention of cardiovascular events in patients with coronary artery disease (CAD) …
Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis
M Valgimigli, PC Smits, E Frigoli… - European heart …, 2022 - academic.oup.com
Aim To assess the effects of 1-or≥ 3-month dual antiplatelet therapy (DAPT) in high
bleeding risk (HBR) patients who received biodegradable-polymer sirolimus-eluting stents …
bleeding risk (HBR) patients who received biodegradable-polymer sirolimus-eluting stents …
Duration of dual antiplatelet therapy for patients at high bleeding risk undergoing PCI
Background The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous
coronary intervention (PCI) among patients at high bleeding risk (HBR) is unknown …
coronary intervention (PCI) among patients at high bleeding risk (HBR) is unknown …
Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease
Multiple guidelines and consensus papers have addressed the role of antithrombotic
strategies in patients with established coronary artery disease (CAD). Since evidence and …
strategies in patients with established coronary artery disease (CAD). Since evidence and …
Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta …
Aims To appraise all available antithrombotic treatments within or after 12 months following
coronary revascularization and/or acute coronary syndrome in two network meta-analyses …
coronary revascularization and/or acute coronary syndrome in two network meta-analyses …
Very short versus longer dual antiplatelet treatment after coronary interventions: a systematic review and meta-analysis
G Tsigkas, A Apostolos, A Trigka… - American Journal of …, 2023 - Springer
Background Very short (≤ 3 months) duration of dual antiplatelet therapy (VSDAPT) has
recently been proposed after percutaneous coronary intervention (PCI) with drug-eluting …
recently been proposed after percutaneous coronary intervention (PCI) with drug-eluting …
Short-term DAPT and DAPT de-escalation strategies for patients with acute coronary syndromes: a systematic review and network meta-analysis
BACKGROUND: Short-term (≤ 6 months) dual antiplatelet therapy (DAPT) and DAPT de-
escalation become attractive for patients with acute coronary syndrome. METHODS: A …
escalation become attractive for patients with acute coronary syndrome. METHODS: A …
Clopidogrel monotherapy after 1-month dual antiplatelet therapy in percutaneous coronary intervention: from the STOPDAPT-2 total cohort
Y Obayashi, H Watanabe, T Morimoto… - Circulation …, 2022 - Am Heart Assoc
Background: The benefit of clopidogrel monotherapy after 1-month dual antiplatelet therapy
(DAPT) compared with 12-month DAPT with aspirin and clopidogrel was demonstrated in …
(DAPT) compared with 12-month DAPT with aspirin and clopidogrel was demonstrated in …